{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:34:18Z","timestamp":1794566058525,"version":"4.9.1"},"reference-count":40,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous type 2 inflammatory disease for which biologic therapies have expanded treatment options; however, biomarkers capable of guiding biologic selection remain poorly defined. This systematic review aimed to evaluate the available evidence regarding predictive and prognostic biomarkers associated with currently available biologic agents for CRSwNP (omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, and tezepelumab). Materials and Methods: A systematic search of PubMed\/MEDLINE, Embase, Google Scholar, and the Cochrane Library identified studies published between January 2006 and September 2025. Results: Twenty-five eligible studies, including 12 randomized controlled trials, 12 systematic reviews\/meta-analyses, and one indirect treatment comparison study, were analyzed. Multiple biomarkers, including blood eosinophils, total IgE, periostin, eotaxins, eosinophil cationic protein, IL-5, TARC, PARC, and urinary leukotriene E4, were evaluated across biologics targeting IgE, IL-4\/IL-13, and IL-5 pathways. Conclusions: Although several biomarkers reflected the modulation of type 2 inflammation and disease activity, no validated biomarker has reliably predicted the superiority of one biologic over another. Nasal IL-5 showed potential for predicting the response to anti-IL-5 therapy but requires further validation. Current evidence supports biomarker use primarily for confirming type 2 inflammation rather than guiding biologic selection. Prospective biomarker-driven and head-to-head comparative studies are needed to enable precision medicine approaches in CRSwNP.<\/jats:p>","DOI":"10.3390\/medicina62061188","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:18:43Z","timestamp":1781860723000},"page":"1188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Use of Biomarkers to Justify the Choice of the Proper Biologic Agent for the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-3694","authenticated-orcid":false,"given":"Georgios X.","family":"Papacharalampous","sequence":"first","affiliation":[{"name":"ORL Department, University Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-2337","authenticated-orcid":false,"given":"Theodora-Eleftheria","family":"Deftereou","sequence":"additional","affiliation":[{"name":"Laboratory of Histology-Embryology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Chaidas","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-1971","authenticated-orcid":false,"given":"Petros V.","family":"Vlastarakos","sequence":"additional","affiliation":[{"name":"2nd University Department of Otorhinolaryngology\u2014Head and Neck Surgery, Attikon University Hospital, 12461 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannis","family":"Constantinidis","sequence":"additional","affiliation":[{"name":"1st Department of Otorhinolaryngology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Katotomichelakis","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jaip.2022.09.043","article-title":"Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology","volume":"11","author":"Seys","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372.","DOI":"10.1136\/bmj.n71"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/bcp.16087","article-title":"Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial","volume":"90","author":"Emson","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: A systematic review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/alr.22473","article-title":"The role of biologics in chronic rhinosinusitis: A systematic review","volume":"10","author":"Iqbal","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/cea.13721","article-title":"Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review","volume":"50","author":"Walter","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/alr.22994","article-title":"The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2022","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/ACI.0000000000000799","article-title":"Clinical and biological markers in disease and biologics to treat chronic rhinosinusitis","volume":"22","author":"Guo","year":"2022","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/1744666X.2020.1679626","article-title":"Endotype-driven precision medicine in chronic rhinosinusitis","volume":"15","author":"Lou","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11882-023-01114-w","article-title":"Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP","volume":"23","author":"Guo","year":"2023","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2020.01.013","article-title":"Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis","volume":"124","author":"Staudacher","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/imt-2019-0191","article-title":"Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis","volume":"12","author":"Boyle","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/ACI.0000000000000540","article-title":"Use of biologics in chronic sinusitis with nasal polyps","volume":"19","author":"Wang","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/1744666X.2015.1010517","article-title":"Emerging biologics for the treatment of chronic rhinosinusitis","volume":"11","author":"Pauwels","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5114\/ada.2020.94842","article-title":"Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps","volume":"37","author":"Novosad","year":"2020","journal-title":"Postep. Dermatol. Allergol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cavaliere, C., Loperfido, A., Ciofalo, A., Di Michele, L., Begvarfaj, E., Bellocchi, G., Bugani, M., de Vincentiis, M., Greco, A., and Millarelli, S. (2024). Real-Life Evidence of Mepolizumab Treatment in Chronic Rhinosinusitis with Nasal Polyps: A Multicentric Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13123575"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e12143","DOI":"10.1002\/clt2.12143","article-title":"Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE)","volume":"12","author":"Contoli","year":"2022","journal-title":"Clin. Transl. Allergy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_38","first-page":"OA2336","article-title":"Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: Results from the phase 3 WAYPOINT study","volume":"66","author":"Lipworth","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Berghi, O., Dumitru, M., Cergan, R., Musat, G., Serboiu, C., and Vrinceanu, D. (2024). Local Allergic Rhinitis-A Challenge for Allergology and Otorhinolaryngology Cooperation (Scoping Review). Life, 14.","DOI":"10.3390\/life14080965"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:08:56Z","timestamp":1781863736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061188"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061188","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}